Pharnext Announces Encouraging Data from Open-Label Phase 3 Extension Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)
- Results suggest sustained safety and efficacy of PXT3003 in CMT1A patients after 25 months of total trial time (Phase 3 trial + open-label extension study)
- CMT1A patients showed improvement or stabilization of disease as measured by the Overall Neuropathy Limitations Scale during the open-label Phase 3 extension study
The Press Release is available at this link: http://s.info.actifin.fr/3706/www/2020/PHARNEXT-CP-20200106-EN.pdf